作者
Penglei Jiang,Hongyu Jia,Xinyue Qian,Tian Tang,Yingli Han,Zhaoru Zhang,Lingli Jiang,Zebin Yu,Lin Zheng,Guodong Yu,Huan Cai,Shanyan Zhang,Xiaoli Zhang,Jueqing Gu,Chanyuan Ye,Lisha Yang,Yingfeng Lu,Heng Liu,Xiaoqing Lu,Ciliang Jin,Yue Ren,Miaomiao Lu,Lingling Xu,Jiong Yu,Xi Jin,Yida Yang,Pengxu Qian
摘要
Chronic hepatitis B (CHB) is caused by HBV infection and affects the lives of millions of people worldwide by causing liver inflammation, cirrhosis, and liver cancer. Interferon-alpha (IFN-α) therapy is a conventional immunotherapy that has been widely used in CHB treatment and achieved promising therapeutic outcomes by activating viral sensors and interferon-stimulated genes (ISGs) suppressed by HBV. However, the longitudinal landscape of immune cells of CHB patients and the effect of IFN-α on the immune system are not fully understood.